Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Pembrolizumab (Immunotherapy)
Treatment for Larynx cancer
Typical Dosage: 200 mg every 3 weeks or 400 mg every 6 weeks IV
Effectiveness
60%
Safety Score
55%
Clinical Trials
7
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
200 mg every 3 weeks or 400 mg every 6 weeks IV
Time to Effect
Weeks to months
Treatment Duration
Up to 2 years or until disease progression/unacceptable toxicity
Evidence Quality
HIGHConfidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150,000
Monitoring:$10,000
Side Effect Mgmt:$5,000
Total Annual:$165,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$300,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$825,000
Cost per Remission
$1,650,000
Pembrolizumab (Immunotherapy) Outcomes
for Larynx cancer
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+20%
Remission Rate
+10%
Common Side Effects
Fatigue
+30%
Pruritus (itching)
+20%
Diarrhea
+15%
Rash
+15%
Hypothyroidism
+10%
Immune-mediated adverse events
+10%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
10 active trials recruiting for Pembrolizumab (Immunotherapy) in Larynx cancer
Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers
NCT04943445ACTIVE NOT RECRUITINGPHASE2
43 participants
INTERVENTIONAL
Fortaleza, Brazil +9 more
Started: Feb 22, 2022
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990RECRUITINGPHASE2, PHASE3
650 participants
INTERVENTIONAL
Birmingham, United States +160 more
Started: Jan 28, 2025
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
NCT04858269RECRUITINGPHASE2
32 participants
INTERVENTIONAL
Winston-Salem, United States
Started: May 27, 2021
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
NCT06295731ACTIVE NOT RECRUITINGPHASE2, PHASE3
410 participants
INTERVENTIONAL
Duarte, United States +86 more
Started: May 14, 2024
Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
NCT04754321RECRUITINGPHASE1
45 participants
INTERVENTIONAL
Columbus, United States
Started: May 12, 2022
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
NCT05172258ACTIVE NOT RECRUITINGPHASE2
52 participants
INTERVENTIONAL
Duarte, United States +19 more
Started: Jul 26, 2022
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT03556228RECRUITINGPHASE1, PHASE2
242 participants
INTERVENTIONAL
Santa Rosa, United States +14 more
Started: Jun 8, 2018
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05721755ACTIVE NOT RECRUITINGPHASE3
290 participants
INTERVENTIONAL
Tampa, United States +50 more
Started: Jun 8, 2023
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT07552558NOT YET RECRUITINGPHASE1, PHASE2
45 participants
INTERVENTIONAL
St Louis, United States
Started: Jun 30, 2026
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
NCT04671667RECRUITINGPHASE2
188 participants
INTERVENTIONAL
Birmingham, United States +176 more
Started: Apr 27, 2021